Chelsie Derman

At the Family Heart Global Summit 2024, Bhatia spoke about the importance of universal Lp(a) screening over only targeted screening.

In an interview O’Donoghue talked about emerging RNA therapies for Lp(a) in phase 2 and 3 trials.

The FDA approves Cobenfy, the first pharmacological approach to treating schizophrenia since the 1970s.

HCPLive spoke to Johnson on how strategies for addressing patient misconceptions about cholesterol management.

At the Family Heart Summit, Nihar Desai, MD, discussed using EMR alerts to improve lipid therapy for high-risk ASCVD, as shown in the PROMPT-Lipid trial.

The analysis of LDL-C Management Trends observed disparities in LDL-C goal attainment by race, gender, and age.

Oral vitamin D improves vitamin D status and quality of life in IBS patients but does not significantly reduce symptom severity, a new study suggests.

With HepQuant DuO and SHUNT tests, investigators could categorize patients with sclerosing cholangitis into low, moderate, and high disease severity subgroups.

A new study finds causal links between schizophrenia and MDD on IBS, highlighting the need for integrated care addressing both psychiatric and gastrointestinal symptoms.

A study revealed erenumab at 140 mg is effective and safe in achieving remission of headaches caused by non-opioid medication overuse.

The model Revised REACH-B outperforms an earlier model by incorporating predictors of predictors of age, sex, platelet count, ALT levels, and positive hepatitis B antigen result.

Inpatients receiving brief cognitive behavioral therapy had a 60% reduced likelihood of suicide attempts and a 71% reduced rate of psychiatric readmissions post-discharge.

A report shows only 24%, 56%, and 62% of patients meet the criteria PSIL-AT for depression according to low-bound, mid-range, and upper-bound estimates, respectively.

A new study revealed those who consume a moderate amount of coffee or caffeine had a 48.1% and 40.7% reduced risk for developing cardiometabolic multimorbidity.

A new study found glucagon-like peptide 1 receptor agonist use was associated with a lower risk of cirrhosis complications for patients with MASLD who did not have cirrhosis.

A new study suggests lower cognitive functioning may be a risk factor for natural cause mortality in people with schizophrenia.

A recent study saw prescription fills for stimulants, and antidepressants increased from 2019 to 2022 but decreased for opioids.

A new study found cannabis-containing cream may be effective at alleviating itch in patients with chronic kidney disease (CKD)-associated pruritus with no adverse events.

In an interview, lead investigator Lauren Moran, MD, shared how the results inform clinical practice on safe amphetamine dosing.

A new study highlights the need for caution when prescribing high-dose amphetamines (≥ 30 mg) due to their psychosis and mania risk.

In a recently published Viewpoint, the authors stress the importance of dermatologists staying updated on prescription cost-saving programs and their impact on patient care.

A phase 3 trial found mirtazapine ineffective in reducing breathlessness in respiratory disease patients, urging caution with off-label antidepressant use.

HCPLive spoke to a healthcare expert who gave his thoughts on the Reagan Udall Foundation for the FDA’s recent meeting to discuss advancing treatments for PTSD.

ChatGPT-4 Vision performed well on text-based radiology test questions but struggled to answer image-related questions.

Semaglutide lowers rates of cardiovascular and COVID-19-related deaths in patients with overweight/obesity, offering promising cardio-metabolic and non-cardiovascular benefits.

The Reagan Udall Foundation hosted a meeting on PTSD treatment needs, with experts and stakeholders highlighting gaps and potential therapies, including MDMA-assisted therapy.

A new study discovers patients with IBD who respond well to high-dose thiamine treatment have an abundance of faecalibacterium prausnitzii.

A study found high error rates in racial and ethnic designations in pediatric health records across 3 Michigan hospitals, risking misinformed care strategies.

In an interview with HCPLive, Wadden discussed the findings of a post-hoc analysis, supporting how semaglutide is not linked to an increased suicidal ideation risk.

A post-hoc analysis of the STEP trials found semaglutide for weight management doesn’t increase depression or suicidal thoughts in individuals without major mental disorders.